Objective The aim of this study was to evaluate the clinical efficacy and safety outcomes of the treatment with cryoballoon (CB) compared to the treatment with traditional irrigated radiofrequency ablation (RF) for pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (pAF) and refractory to antiarrhythmic drug therapy (AAD). Design We conducted a systemic review to find and include more than two randomized controlled trials (RCTs) with at least 20 patients in each of the CB and RF groups. Thereafter, we performed a meta-analysis to compare the treatment with CB and RF in primary outcomes including 1 year free from AF, complications and re-ablation procedures. Additionally, we evaluated procedure time and fluoroscopy duration in both groups. Risk of bias in the individual studies and across studies was assessed using Cochrane methods. Data extraction and synthesis Two reviewers extracted study data and assessed risk of bias. Primary outcome data were extracted from the time point 1 year after the procedure. The random-effects model was used to calculate the odds ratio with 95% confidence interval. Data sources Data sources utilized were PubMed and CENTRAL databases up to 16 June 2016. Eligibility criteria for selecting studies Included studies were RCTs in adults with pAF and refractory to AAD in which CB therapy, including 1st and 2nd generation CB, was compared to the traditional irrigated RF therapy. Clinical outcomes assessed in each RCT were 1 year AF-free survival, complication rates, re-ablations, fluoroscopy time and procedure time. Results The systematic review identified four randomized controlled trials that reported on comparative clinical outcomes involving 1284 patients. Our meta-analysis demonstrated that CB ablation had a non-significant higher success rate than RF therapy (OR 1.13; 95% CI 0.72-1.77). However, our study showed a relatively higher rate of complications in the CB group (OR 1.20; 95% CI 0.58-2.52). Furthermore, CB treatment was associated with a non-significant, shorter procedure time and marginally prolonged fluoroscopy time in comparison to RF treatment. Conclusion Our systemic review and meta-analysis revealed further evidence that cryoballoon ablation is an equally effective alternative procedure to the standard radiofrequency treatment with a slightly, non-significant higher freedom from AF 1 year after the ablation and a shorter procedure time.
Introduction
Paroxysmal atrial fibrillation (pAF) is a common type of arrhythmia that is defined by an irregular and often fast heartbeat. This arrhythmia is associated with a reduced quality of life, high costs and increased mortality [33, 37] .
Multiple randomized and non-randomized studies demonstrated that pulmonary vein isolation (PVI) is an effective treatment for drug-refractory pAF when compared to antiarrhythmic pharmacotherapy (AAD) alone [5, 32, 36] .
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The traditional method is a point-by-point ablation of the circumference of the pulmonary veins using irrigated radiofrequency (RF) energy emitting catheters (Fig. 1) . A novel technology uses a cryoballoon (CB) to be placed in the pulmonary vein ostia, which then delivers freezing energy to isolate the pulmonary veins circumferentially in a single shot. Several randomized head-to-head comparisons between the two technologies have been performed [16, 20, 23, 31] . CB ablation may require a shorter learning curve, more radiation and shorter procedure times according to some authors (Aryana et al. [2] , Mugnai et al. [28] ).
The rationale of our meta-analysis was to explore the efficacy and safety profiles of CB versus RF therapy from randomized controlled trials (RCTs) comparing the two interventions.
Methods
Before starting this systematic review and meta-analysis, a review protocol was developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [27] .
Eligibility criteria
In our systemic review and meta-analysis, we aimed to include RCTs to evaluate the clinical efficacy and safety outcomes of the treatment with CB compared to the treatment with traditional irrigated RF for PVI in patients with drug-refractory pAF.
Studies for inclusion fulfilled the following criteria: (1) patients of all ages, both genders and any ethnicity with pAF refractory to drug therapy who then accepted catheter ablation; (2) patients with the treatment of catheter ablation for the first time; (3) comparison between CB and RF ablation (4) intervention with first or second generation cryoballoon (5) sample size of at least 20 patients in each group; (6) study was a minimum of 1 year in duration; (7) outcome data existing with a follow-up of 1 year for success rate, complication rates, re-ablation procedures, procedure time and fluoroscopy time. Success rate was defined in our study as freedom from documented AF recurrence 1 year after ablation. Each documented episode over 30 s following a 3 month blanking period was considered a failure, as per current guidelines [6] . Complications were defined as nonarrhythmia related adverse events that occurred during or immediately after the procedure (Table 3) .
The exclusion criteria were as follows: (1) study being observational; non-randomized and/or multifactorial in design; (2) conference abstracts, case reports, review articles, or non-English articles, (3) studies with both paroxysmal and persistent AF patients.
Information sources
This systematic review and meta-analysis comprised electronic searches in PubMed and CENTRAL databases. The language of the research papers was limited to English.
Search
The literature was searched using the terms 'atrial fibrillation' or 'atrial fibrillation' (MeSH Terms) or AF (title/ abstract) and 'cryoballoon' (title/abstract) or 'cryothermal' (title/abstract) or 'cryotherapy' (titel/abstract). The literature search was conducted until 16 June 2016.
Study selection
The studies for this analysis were reviewed and evaluated by two independent investigators (AA, and MIM) according to the following PRISMA guidelines [27] : (1) clear definition of study population, outcomes, and outcome assessment; (2) independent assessment of outcome measurements; (3) sufficient duration of follow-up; (4) no selective loss of follow-up; and (5) identification of important cofounders and prognostic factors. Any disagreements were resolved by discussion with the other authors. 
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Data extraction
Data collection process and data items
From each qualified article, two reviewers (RV and MY) independently extracted the following data into a standard Excel template: (1) author's name, publication year, sample size and characteristics of trial participants (including mean age, gender, mean CHADS-VASc-Score, hypertension (HTN), left atrial (LA) diameter, coronary artery disease (CAD), stroke/transient ischemic attack (TIA), diabetes mellitus); Additionally, information was acquired from each included trial on: (2) type of intervention (including type of ablation, technique and catheter used); (3) type of outcome measure (primary outcome data including success rate 1 year after ablation, complications and reablations, as well as procedure time and fluoroscopy time). Data extraction was conducted by joint agreement, and all potential disagreement was resolved by consensus. We contacted one author for further information, though the author did not respond to our enquiry.
Risk of bias in individual studies
To ascertain the validity of included RCTs, two reviewers working independently assessed the risk of bias using the method delineated in the Cochrane Collaboration Handbook for Systematic Reviews of Interventions [14] . Risk of bias was evaluated as high, low and unclear in each RCT for the following six domains: randomization sequence generation, allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome data (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias.
Statistical analysis
Summary measures and synthesis of results
The meta-analysis of the summary statistics from the individual trials was conducted using STATA software (StataCorp, College Station, TX, version 14.1 for Windows). The statistical analysis was completed by two independent reviewers (RV and MIM). We aimed to assess more then two RCTs with at least 20 patients in each group, fulfilling the criteria mentioned above in our analysis. The odds ratios (OR) with 95% confidence interval from each individual trial were pooled using a random-effects model with inverse-variance weighting. The primary outcome measures included success rate, complications and re-ablations.
A random-effects model was more suitable than a fixedeffects model for our analysis since we expected to observe between-study variation additionally to within-study error in the true effects across studies. The between-study variation might be due to the fact that independently operating researchers performed all of the studies. Because of this, a between-study variation due to slight disparities in CB technique and a different learning curve could be assumed.
The between-study heterogeneity was assessed and quantified using the inconsistency index (I 2 ) statistic (I 2 < 25% = low, I 2 : 25-50% = moderate and I 2 > 50% high heterogeneity).
For continuous outcome data, which indicated only median, interquartile range (IQR) and size of sample, we estimated the mean according to previous published papers to pool data [15] . We estimated the standard deviation (SD) from the IQR (SD = IQR/1.35) according to the Cochrane Collaboration Handbook for Systematic Reviews of Interventions [14] .
Sensitivity analyses were performed to evaluate the contribution of each study to the pooled effect estimate by sequentially removing each trial one at a time and recalculating the pooled OR estimates for the remaining studies [4] .
Risk of bias across studies
We evaluated the likelihood of publication bias by assessing a funnel plot of the study mean differences for asymmetry. We concede that other factors, such as variances in trial quality or true study heterogeneity, could cause asymmetry in funnel plots [14] .
Results
Identified and eligible studies
Study selection
The selection procedure with flow diagram for the included clinical studies is shown in Fig. 2 . Initially, 706 potentially relevant articles were identified in the preliminary literature search, of which 662 were excluded after reviewing the titles and abstracts. Of the 44 trials that were retrieved for further examination, 40 articles were excluded on the basis of full-text detailed review. Ultimately, four qualified articles involving 1284 patients referred for catheter ablation were included for analysis [16, 20, 23, 31] .
Characteristics of included studies
The summary of study characteristics is listed in Table 1 . The main differences of the studies are the number of patients included, catheter generation and follow-up method. Inclusion criteria of each study were all equal to our study.
Of the 1284 patients from all selected trials, 374 patients received the CB ablation procedure and 376 the RF procedure. The main characteristics at baseline, including distribution of age, LA diameter and diabetes mellitus were comparable between patients referred for CB and RF ablation (P > 0.05) (characteristics of patients are summarized in Table S1 in the Supplementary Appendix).
Risk of bias within studies
Results of the assessment of risk of bias are summarized in Fig. 3 . Risk of bias was evaluated as high (red), low (green) and unclear (yellow) for each domain in every RCT.
Since all four studies were RCTs, the risk of bias was low in most categories. Selection bias was very low in all trials, because all studies used well-established randomization methods. However, blinding of the physicians performing the procedures was not possible due to the nature of the procedure. Likewise, patients could not be blinded to the treatment allocation since the procedures were performed under conscious sedation or general anesthesia.
In the FIRE and ICE and the FreezeAF trial, outcome data were not complete. Especially in the latter, a total of 22 patients out of 315 patients (7%) were lost to followup. Furthermore, both of these trials used composite or co-primary endpoints, which could also increase the risk of other bias.
The FreezeAF study also had a high risk of detection bias because adjudicators were not blinded to the group assignment on the determination of AF recurrence. 
Meta-analysis results
Freedom of atrial fibrillation recurrence after 1 year
The freedom of AF recurrence 1 year after catheter ablation was relatively higher in patients referred to CB ablation than RF ablation (OR 1.13; 95% CI 0.72-1.77) ( Table 2 ; Fig. 4 ). The I 2 , which quantified heterogeneity between trails, was 60.3% suggesting substantial evidence of between-trial heterogeneity. It is worth noting that the wide confidence intervals generated might result from the small sample size of clinical trials involved, which is especially applicable for the CORtrial [31] .
Complication and re-ablation rate
The pooled analysis of complications showed a relatively higher risk with CB ablation (OR 1.20; 95% CI 0.58-2.52) (Fig. 5) . The specific entities of complications are listed in Table 3 . The re-ablation procedures were performed non-significantly more often in the CB group (OR 1.07; 95% CI 0.65-2.52, Fig. 6 ). As indicated by the I 2 statistic, heterogeneity was intermediate for complications (I 2 = 52%; P = 0.099), and low for the re-ablation procedures (I 2 = 18.9%; P = 0.296).
Fluoroscopic time and procedure time
CB ablation reduced procedure time non-significantly by a weighted mean of 13.5 compared with RF ablation (Fig. 7) . The fluoroscopy time, though, was non-significantly prolonged with CB ablation by a weighted mean of 3.6 (Fig. 8 ).
The I 2 was 87% for total procedure time and 66% for fluoroscopic time implying strong evidence of between-trial heterogeneity.
Risk of bias across studies
For the primary outcome, we assessed the risk of bias across studies, and in particular, publication bias using funnel plots (Figures S1-S3 in the Supplementary Appendix). However, since we only found four studies fulfilling all inclusion criteria, the funnel plots have limited significance in their statement. All three funnel plots show very asymmetric distribution.
Sensitivity analysis
Sensitivity analyses were performed for the primary outcome measures to assess the contribution of each study to the pooled effect estimate by sequentially removing each trial one at a time and recalculating the pooled OR estimates for the remaining studies [4] . The results of the sensitivity analysis are listed in Table S2 in the Supplementary   Fig. 3 Risk of bias assessment for included studies Appendix. There was not an individual study influencing the overall effect significantly for all examined comparison.
Discussion
Statement of principal findings
Our meta-analysis is the first attempt to compare CB and RF ablation in pAF patients by focusing on similar conducted published RCTs.
In our meta-analysis, we confirmed that the CB ablation is an effective alternative strategy to point-by-point RF ablation for the treatment of pAF. Although the CB treatment was not found to be significantly better than RF, there was a difference in success rates favoring CB treatment (OR 1.13; 95% CI 0.72-1.77).
Furthermore, both CB and RF treatments showed a similar low overall complication rate (CB 8.4% vs. RF 7.2%) with a large distribution in the entity of complications. The relatively higher rate in complications in the CB group (OR 1.20; 95% CI 0.58-2.52) could be explained by the high rate of transient and persistent phrenic nerve palsies which occurred exclusively in the CB group. However, from the 23 patients diagnosed with phrenic nerve palsy, only one had an unresolved persistent phrenic palsy after 12 months. Especially, reported after RF therapy were cardiac tamponade, pericardial effusion and groin-side complications including bleeding and arteriovenous fistula. In general, the complication rate was very low in both groups, which reassures that both ablation techniques are safe to perform.
Additionally, similar to previous studies, we demonstrated that CB ablation is associated with a relatively shorter procedure time [13, 28, 35] . The reason for the shorter procedure Contrastingly, there was an extended fluoroscopy exposure in the CB technique in this meta-analysis. Longer fluoroscopy time in the CB group might be explained by the need for a higher resolution and prolonged time to prove balloon placement and occlusion of the pulmonary vein.
Strengths and weaknesses of the study
While there have been previous meta-analysis of studies comparing CB with RF treatment, this analysis is the first to include only RCTs, which is still considered to be the 'gold standard' for clinical trials [25] .
Despite the clear strength of this meta-analysis, some limitations should be considered. Although the selected studies are all RCTs and compare CB versus RF in patients with pAF, they differ in methods, protocols and strategies in the individual RF and CB groups.
In all four RCTs, RF ablation was delivered using a 3.5 mm-irrigated tip ablation guided by a three-dimensional mapping system (CARTO3, Biosense Webster) to isolate the PV ostia in ipsilateral pairs. The procedure endpoint was bidirectional PV conduction block. In the study by Kuck et al. [20] , additional strategies such as LA lesions or complex fractionated atrial electrogram were not allowed. Whereas in the studies by Luik et al. [23] and Perez-Castellano et al. [31] additional applications could be used if considered necessary. The study by Hunter et al. [16] did not explicitly mention if further procedures were permitted.
Three of the four studies demonstrated that standard, first-generation, irrigated-tip ablation catheters were used for RF ablation (ThermoCool Biosense Webster). It should be emphasized that only in the study by Kuck et al. [20] , more advanced catheters were applied in addition to the standard catheter (ThermoCool SF and ThermoCool SmartTouch). The ThermoCool SF catheter with surround flow technology provides a uniform cooling of the entire catheter tip during ablation. The newest generation catheter (ThermoCool SmartTouch) is also a surround flow catheter, but has the ability of contact-force measurements. This catheter significantly differs from the previous generations since it gives users feedback according to contact force of lesion application, verification of contact on tissue, and direction of catheter [29] . The use of real-time contact force sensing technology for RF ablation compared to conventional irrigated radiofrequency ablation showed in some recent studies potential benefit with reduction of AF recurrence [17, 24] . Therefore, if this new technology was used in all patients of the RF groups, the results of this meta-analysis might have been in favor of the RF procedure.
The four RCTs also differed significantly in their freezing protocols of the CB groups. In the study by Hunter et al. (2014) , only first-generation CBs (Artic Front, Medtronic Inc.) were used and at least two 5-min freezes were performed at each PV ostium with temperatures of ≤ − 40 °C. Similar to this protocol, Perez-Castellano et al. [31] also included only first-generation CBs, but two 300-s cryoenergy applications were delivered. On the contrary, in the study by Kuck et al. [20] and by Luik at al. [23] , first-and second-generation CB were used (Artic Front and Artic Front Advance, Medtronic Inc.). Two applications were performed with a target ablation time of 300 s, when using the Arctic Front catheter and 240 s, when using the Arctic Front Advance catheter. The second generation of the CB is considered to be more effective than the first generation, since it has a larger surface area of coolant distribution. It has been shown to be superior to first-generation CB in several comparative studies and to improve acute and long-term outcomes of PV isolation [11, 12, 21, 26, 30] .
In all four studies, two different sizes of CB were available (23-and 28-mm diameter) and selection depended on the size of the PV ostia and the preference of the physicians. Additionaly, Hunter et al. (2014) stated that, if PV ablation failed with the regular CBs, focal ablation was allowed with an 8 mm cryoablation catheter (Freezor Max, Medtronic).
In general, studies comparing the newest RF technology using contact force sensing with a surround flow catheter versus the second-generation cryoballoon are very limited. There are only some observational, non-randomized studies showing comparable outcomes of the two techniques [18, 34] . It should be pointed out, that one large multi-center, randomized trial known as the CIRCA-DOSE trial involving 348 participants is currently active (https ://clini caltr ials. gov/ct2/show/NCT01 91352 2) and first results are expected to be published at the end of the year 2018. The aim of this study is to assess the effectiveness of contact-force-assisted RF PVI versus PVI performed with the second-generation CB, and to evaluate the optimal cryoablation duration [1] .
Another limitation of this study was that all four RCTs included in the meta-analysis were conducted in different centers with different experience of operators and may be slightly incongruent in procedure processes. Notably, Hunter et al. (2014) demonstrated that the learning curve with CB has a significant impact on the success rate of isolating all four pulmonary veins (PVs). Over the course of the study, it increased from 62% in the first third of the study patients to 77% in the latter third.
The detection method of AF recurrence was also determined differently in each study. Perez-Castellano et al. [31] used an implanted Reveal recorder, whereas, Holter monitors were applied for the detection of AF in other studies. Previous trials indicate that the external monitoring methods are limited compared to implantable Reveal loop recorder [8] .
Two studies [20, 23] assessed composite primary endpoints in their noninferiority, prospective study. Composite endpoints are often used in cardiovascular trials and might lead to data extraction errors [9] . Because Kuck et al. revealed the components of his composite primary endpoint including recurrent atrial arrhythmia, we could use this data for our analysis. Luik et al. [23] did not specifically indicate the components of the co-primary endpoint, which was defined as the absence of AF in combination with absence of persistent complications during the 12-month follow-up period. We contacted the author to obtain the exact number of AF recurrence after 1 year, but received no response. Since the paper states no persistent complications at the 12-month follow-up, we estimated that the primary endpoint was equal to the absence of atrial fibrillation at that point in time. Lastly, although RCTs may be the 'gold standard' for quantifying effect estimates and minimizing bias, they may not be applicable to patients treated in general clinical practice [3] .
Moreover, there are some limitations to our methodological approach. For instance, we estimated the mean and SD for continuous data with a formula established under the assumption that the data are normally distributed [14] . However, the median and quartiles are often reported in studies when data do not follow a normal distribution and consequently our calculation might not be absolutely precise.
Additionally, the quality of the studies assessed with the risks of biases varied. Randomization was appropriate in all trials, but the blinding of patients and personnel was not possible. Furthermore, two studies had incomplete outcome data due to patients lost to follow-up.
Publication bias might also account for some of the effects we observed. All funnel plots showed an asymmetric distribution, which indicates the risk of either publication bias or small study effect [14] .
Strengths and weaknesses in relation to other studies
There have been two meta-analyses about pAF ablation published recently, but these studies differ significantly in the study inclusion criteria from our study. Liu et al. [22] published a meta-analysis this year that included retrospective, prospective, randomized and non-randomized studies. Furthermore, all different ablation methods and all different stages of AF (pAF, persistent and permanent) were included. They showed that CB ablation was associated with a greater freedom from atrial fibrillation than RF; however, the follow-up period of the included studies ranged from 3 to 25 months. Therefore, results of these studies are very inhomogeneous and might effect the meta-analysis in an unreliable way. In 2014, another meta-analysis was published by Xu et al. [38] , which mainly included non-randomized trials and most of the studies did not evaluate the success rates after ablation. The main results of this meta-analysis were similar to ours, but in contrast to our study, fluoroscopic time was improved in patients referred to CB ablation.
Meaning of the study: possible explanations and implications for clinicians and policymakers
Since CB ablation is as effective as standard RF ablation without higher complication rates, both procedures should have the same recommendation level for clinicians and should be offered equally to patients with pAF. Still, some other aspects of this newer intervention should be considered. For example, CB ablation is less painful than RF ablation, and therefore, some patients might prefer this treatment to the RF therapy [10] .
In addition, some publications demonstrated that CB ablation of PVs is a simple and straightforward procedure with a faster learning curve than RF ablation [7, 19] . Thus, some electrophysiologist in training might have a higher success rate after PVI with this newer technology. Lastly, CB was designed to prevent the need for a mapping system and application of multiple ablation lesions to achieve shorter procedure times. The shorter procedure time could lead to a more cost-effective approach for hospitals due to a potential increase in ablations conducted per day.
Unanswered questions and future research
All included studies still used the first generation CB catheter and older generation RF catheters. Further multicenter studies are needed to compare the newest generation of CB and RF technologies to give an up-to-date recommendation of the superior treatment.
Furthermore, future research should investigate if a specific subgroup of patients would benefit more from CB or RF treatment. For example, RF might be better suited for younger patients, since in RF ablation, the fluoroscopic time is relatively shorter than with CB. In addition, specific anatomic variations of the PV might lead to a lower success rate in the CB approach than with RF, because the balloon could be more difficult to place, potentially leading to a failure of complete pulmonary vein isolation.
Conclusion
In summary, our meta-analysis demonstrated that CB ablation is an equally effective and safe alternative procedure to the standard radiofrequency treatment. Although the CB treatment was not significantly better than RF, there was a non-significant difference in success rates favoring CB treatment. Moreover, CB treatment consists in a non-significant shorter procedure time, albeit with a longer fluoroscopic time. In both technologies, pAF ablation seems to be a treatment with a high success rate and very few complications.
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